January was kind to the major asset classes, marking a strong rebound from a rough month in December. Read more here.

The PIMCO Corporate and Income Opportunity Fund aims for maximum total return through current income and capital appreciation ...

In Q2 FY2025, Microsoft outperformed top and bottom line estimates, with total revenues increasing +12% y/y to $69.6B (vs.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

IBM's Q4 report shows strong growth, driven by GenAI tailwinds, with AI bookings exceeding $5 billion. See why I reiterate my ...

Geopolitical tensions and an uncertain inflation outlook rattled markets in the fourth quarter but U.S. stocks still managed ...

Public Service Enterprise Group's capex commitments limit growth. Read why PSEG stock is a sell and why Consolidated Edison ...

Veradigm (MDRX) ends strategic review after receiving no firm proposals. Potential bidders included McKesson, Oracle, and Thoma Bravo.

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Discover why the Fidelity Mid Cap Value Fund (FSMVX) is a top choice for conservative investors seeking strong performance ...